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responsibility of XAbstract This paper describes a simple, rapid and sensitive liquid chromatography–tandem mass
spectrometry assay for the determination of duloxetine in human plasma. A duloxetine stable
labeled isotope (duloxetine d5) was used as an internal standard. Analyte and the internal standard
were extracted from 100 mL of human plasma via solid phase extraction technique using Oasis HLB
cartridges. The chromatographic separation was achieved on a C18 column by using a mixture of
acetonitrile–5 mM ammonium acetate buffer (83:17, v/v) as the mobile phase at a ﬂow rate
of 0.9 mL/min. The calibration curve obtained was linear (r2Z0.99) over the concentration range of
0.05–101 ng/mL. Multiple-reaction monitoring mode (MRM) was used for quantiﬁcation of ion
transitions at m/z 298.3/154.1 and 303.3/159.1 for the drug and the internal standard, respectively.
Method validation was performed as per FDA guidelines and the results met the acceptance
criteria. A run time of 2.5 min for each sample made it possible to analyze more than 300 plasma
samples per day. The proposed method was found to be applicable to clinical studies.
& 2013 Xi’an Jiaotong University. Production and hosting by Elsevier B.V. All rights reserved.ersity. Production and hosting by E
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in (N.R. Pilli)
i’an Jiaotong University.1. Introduction
Duloxetine hydrochloride (CAS no.: 136434-34-9), is a
balanced selective serotonin and norepinephrine reuptake
inhibitor. The drug is used in the treatment for major
depression [1], pain related to diabetic peripheral neuropathy
[2,3], and stress urinary incontinence [4]. Duloxetine has
a low afﬁnity toward serotonergic, cholinergic, adrenergic,
and histamine receptors, and this speciﬁcity of action
accounts for its greater safety proﬁle with respect to tricycliclsevier B.V. All rights reserved.
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Quantiﬁcation of duloxetine in human plasma by LC–MS/MS 37antidepressants [5–7]. Usually duloxetine is administered in
the form of capsules dosage form containing 20, 30 or 60 mg
of active constituent in enteric-coated pellets and the most
common doses for the treatment of major depression are
40–60 mg daily.
As per the literature, numerous analytical methods have
been reported for the determination of duloxetine which
include liquid chromatography–tandem mass spectrometric
methods (LC–MS/MS) [7–12], liquid chromatography with
single-quadrupole mass spectrometric method (LC–MS)
[13,14], gas chromatographic mass spectrometric method
[15], capillary electrophoresis method [16] and high perfor-
mance liquid chromatographic (HPLC) methods [17,18].
Of all the above, only ﬁve methods [8,9,12–14] are compar-
able with the present work. The method proposed by Ma
et al. [13] and Choong et al. [14] described a single-
quadrupole mass spectrometry (LC–MS) with selected-ion
monitoring (SRM) mode to detect the precursor ion. But in
the present method, a triple-quadrupole mass spectrometry
(LC–MS/MS) with multiple-reaction monitoring (MRM)
mode was used to detect both the precursor ion and fragment
ion. It shows that the proposed method is highly speciﬁc.
Moreover, the method proposed by Choong et al. [14] utilizes
multi-step solid-phase extraction with an LLOQ of 2 ng/mL
which is not sensitive enough and involving complexity like
gradient elution, typical mobile phase consisting of two or
more buffers with the pH adjustment, longer chromato-
graphic run time (413 min). Another method was reported
by Selvan et al. [8] for the determination of duloxetine in
human plasma with plasma concentration range of
0.1–50 ng/mL by using liquid chromatography with atmo-
spheric pressure ionization–tandem mass spectrometry. This
method employs protein precipitation (PP) method for the
sample preparation. PP is most likely to cause ion suppres-
sion, since this method fails to sufﬁciently remove endogen-
ous compounds such as lipids, phospholipids, fatty acids, etc.
[19–21]. Recently Reddy et al. [12] reported an LC–MS/MS
method for the determination of duloxetine in 300 mL of
human plasma with an LLOQ of 0.1 ng/mL, this method
employs liquid–liquid extraction (LLE), evaporation, drying
and reconstitution for sample preparation. The salient fea-
tures of chromatographic methods developed for duloxetine
in human plasma are summarized in Table 1.
The present work describes a simple, selective and sensitive
method, which employs solid phase extraction (SPE) techni-
que (SPE) for sample preparation and liquid chromatography
with electrospray ionization–tandem mass spectrometry
for quantitation of duloxetine in 100 mL of human plasma.
SPE is the most popular sample pre-treatment approach
nowadays due to following advantages: high recovery, effec-
tive pre-concentration, the need for less organic solvent
(compared to LLE), no foaming in the formation of emul-
sions, ease of operation and greater possibility of automation
[19–21]. The method uses duloxetine d5 as an internal
standard (IS). The use of stable labeled isotopes of the
duloxetine as an IS increases the assay precision and limits
variable recovery between the analyte and the IS. Application
of this assay method to a clinical pharmacokinetic study in
healthy male volunteers following oral administration of
duloxetine is described. The authenticity in the measurement
of study data is demonstrated through incurred samples
reanalysis (ISR).
R. Gajula et al.382. Experimental
2.1. Chemicals
Duloxetine hydrochloride reference standard (99.6% pure) was
obtained from Hetero Labs Limited (Hyderabad, India). Dulox-
etine d5 oxalate (100.0% pure) was employed as an IS and was
obtained from Clearsynth Labs Limited (Mumbai, India). Their
structures are shown in Fig. 1. HPLC grade acetonitrile was
purchased from J.T. Baker (Phillipsburg, USA). Analytical grade
formic acid and ammonium acetate were purchased from Merck
Ltd (Mumbai, India). Water used for the LC–MS/MS analysis
was prepared by using Milli Q water puriﬁcation system
procured from Millipore (Bangalore, India). The control human
plasma sample was procured from Deccan’s Pathological Lab’s
(Hyderabad, India).
2.2. LC–MS/MS instrument and conditions
An HPLC system (Shimadzu, Kyoto, Japan) consisting of a
Zorbax SB C18 column (50 mm 2.1 mm, 5 mm; Agilent Tech-
nologies, Santa Clara, CA, USA), a binary LC-20AD promi-
nence pump, an auto-sampler (SIL-HTc) and a solvent degasser
(DGU-20A3) was used for the study. Aliquot of 10 mL of the
processed samples was injected into the column, which was kept
at 40 1C. An isocratic mobile phase consisting of a mixture of
acetonitrile–5 mM ammonium acetate buffer (83:17, v/v) was
used to separate the analyte from the endogenous components
and delivered at a ﬂow rate of 0.9 mL/min into the electrospray
ionization chamber of the mass spectrometer. Quantiﬁcation was
achieved with MS–MS detection in positive ion mode for the
analyte and the IS using an MDS Sciex API-4000 mass spectro-
meter (Foster City, CA, USA) equipped with a Turboionspray
TM
interface at 500 1C. The ion spray voltage was set at 5500 V. The
source parameters viz. the nebulizer gas (GS1), auxiliary gas
(GS2), curtain gas and collision gas were set at 40, 42, 20, and
6 psi, respectively. The compound parameters viz. the decluster-
ing potential (DP), collision energy (CE), entrance potential (EP)
and collision cell exit potential (CXP) were 18, 10, 10, 10 V forDuloxetine hydrochloride 
O
S
N
H
D D
CD3
HOOCCOOH
Duloxetine d5 oxalate (IS)
Fig. 1 Chemical structures of duloxetine hydrochloride and
duloxetine d5 oxalate (IS).duloxetine and 18, 9, 10, 9 V for the IS. Detection of the ions was
carried out in the MRM mode, by monitoring the transition
pairs of m/z 298.3 precursor ion to the m/z 154.1 for duloxetine
and m/z 303.3 precursor ion to the m/z 159.1 product ion for the
IS. Quadrupoles Q1 and Q3 were set on unit resolution. The
analysis data obtained were processed by Analyst Software
TM
(version 1.4.2).
2.3. Preparation of plasma standards and quality controls
Standard stock solutions of duloxetine and IS (1 mg/mL) were
prepared in methanol. Working solutions for calibration and
controls were prepared by appropriate dilution in water–
methanol (60:40, v/v; diluent). The IS working solution
(200 ng/mL) was prepared by diluting its stock solution with
diluent.
Calibration samples were prepared by spiking 950 mL of
control human plasma with the 50 mL working standard solution
of the analyte as a bulk, to obtain duloxetine concentration levels
of 0.05, 0.10, 0.51, 2.53, 5.05, 10.1, 20.2, 40.4, 80.9 and 101 ng/mL
as a single batch at each concentration. Similarly, quality control
(QC) samples were also prepared as a bulk based on an
independent weighing of standard drug, at concentrations of
0.05 (LLOQ), 0.15 (low), 15.7 (middle 1), 50.6 (middle 2) and
90.2 ng/mL (high) as a single batch at each concentration. The
calibration and control bulk samples were divided into aliquots in
micro centrifuge tubes (Tarson, 2 mL) and stored in the freezer at
70710 1C until analyses.
2.4. Sample processing
A 100 mL aliquot of human plasma sample was mixed with
10 mL of the IS working solution (200 ng/mL of duloxetine
d5). To this, 25 mL of 0.1% formic acid solution was added
after vortex mixing for 10 s. The sample mixture was loaded
onto an Oasis HLB cartridge (30 mg/mL) that was pre-
conditioned with 1.0 mL of methanol followed by 1.0 mL of
water. The extraction cartridge was washed with 1.0 mL of
0.1% formic acid solution followed by 1.0 mL of 5% metha-
nol. Analyte and IS were eluted with 0.5 mL of mobile phase.
Aliquot of 10 mL of the extract was injected into the
chromatographic system.
2.5. Bioanalytical method validation
The validation of the above method was carried out as per US
FDA guidelines [22]. The parameters determined were selec-
tivity, speciﬁcity, sensitivity, matrix effect, linearity, precision,
accuracy, recovery, dilution integrity and stability. Selectivity
was assessed by comparing the chromatograms of six different
batches of blank plasma obtained from six different sources
including one lipemic and hemolyzed plasma. Potential inter-
ference from acetaminophen, diphenhydramine, pantoprazole,
nicotine, ibuprofen, caffeine and pseudoephedrine was eval-
uated. Sensitivity was determined by analyzing six replicates of
plasma samples spiked with the lowest level of the calibration
curve concentrations. Matrix effect was checked with six
different lots of K2EDTA plasma. Three replicate samples
each of LQC and HQC were prepared from different lots
of plasma (36 QC samples in total). For checking the
linearity standard calibration curves containing at least
Quantiﬁcation of duloxetine in human plasma by LC–MS/MS 3910 points (non-zero standards) were plotted. In addition, blank
plasma samples were also analyzed to conﬁrm the absence
of direct interferences. Intra-day precision and accuracy were
determined by analyzing six replicates at ﬁve different QC levels
on two different days. Inter-day precision and accuracy were
determined by analyzing six replicates at ﬁve different QC levels
of ﬁve different runs. Recoveries of analyte and IS were
determined by comparing the peak area of extracted analyte
standard with the peak area of non-extracted standard. Recov-
eries of duloxetine were determined at concentrations of 0.15
(low), 50.6 (middle 2) and 90.2 (high) ng/mL, whereas for IS was
determined at a concentration of 200 ng/mL. Dilution integrity
was performed to extend the upper concentration limit with
acceptable precision and accuracy. Six replicates each at a
concentration of about 1.7 times of the uppermost calibration
standard were diluted two- and four-fold with blank plasma.
The diluted samples were processed and analyzed.
Stability tests were conducted to evaluate the analyte stability
in stock solutions and in plasma samples under different
conditions. The stock solution stability at room temperature
and refrigerated conditions (2–8 1C) was performed by compar-
ing the area response of the analyte (stability samples) with the
response of the sample prepared from fresh stock solution. Bench
top stability (8 h), processed samples stability (autosampler
stability for 48 h, wet extract stability for 24 h and reinjection
stability for 24 h), freeze–thaw stability (three cycles), long-term
stability (58 days) were performed at LQC and HQC levels using
six replicates at each level. Samples were considered to be stable
if assay values were within the acceptable limits of accuracy
(715% SD) and precision (r15% RSD).
2.6. Pharmacokinetic study design
A pharmacokinetic study was performed in healthy male subjects
(n¼6). The Ethics Committee (Hyderabad Independent Ethics
Committee, Hyderabad, India) approved the protocol and the
volunteers provided with informed written consent. The subjects
were fasted 10 h before administration of the drug formulation.
Blood samples were collected following oral administration of
duloxetine hydrochloride (60 mg) at pre-dose and 0.5, 1, 1.5, 2,
2.5, 3, 3.5, 4, 4.33, 4.67, 5, 5.33, 5.67, 7, 7.5, 8, 9, 10, 12, 24, 36, 48,
and 72 h, post-dose in K2EDTA vacutainer collection tubes (BD,
Franklin, NJ, USA). The tubes were centrifuged at 3200 rpm for
10 min and the plasma was collected. The collected plasma
samples were stored at 70710 1C till their use. Plasma samples
were spiked with the IS and processed as per the extraction
procedure described earlier. Along with the clinical samples, the
QC samples at low, middle 1, middle 2 and high concentration
levels were also assayed in triplicate. Plasma concentration–time
proﬁle of duloxetine was analyzed by non-compartmental method
using WinNonlin Version 5.1. An incurred sample reanalysis was
also conducted by selecting the 12 subject samples (2 samples
from each subject) near Cmax and the elimination phase. The
percent change in the value should not be more than720% [23].3. Results and discussion
3.1. Method development
To develop a rapid, sensitive and simple assay method for the
extraction and quantiﬁcation of duloxetine during methoddevelopment different options were evaluated to optimize detec-
tion and chromatography parameters. The inherent selectivity of
MS/MS detection was also expected to be beneﬁcial in develop-
ing a selective and sensitive method. Protonated form of analyte
and IS, [MþH]þ ion was the parent ion in the Q1 spectrum and
was used as the precursor ion to obtain Q3 product ion spectra.
The most sensitive mass transition was observed from m/z 298.3
to 154.1 for duloxetine and from m/z 303.3 to 159.1 for the IS.
As earlier publications have discussed the details of fragmenta-
tion patterns of duloxetine [12], we are not presenting the data
pertaining to this. LC–MRM is a very powerful technique for
pharmacokinetic studies since it provides sensitivity and selectiv-
ity requirements for analytical methods [24]. Thus, the MRM
technique was chosen for the assay development. The MRM
state ﬁle parameters were optimized at a concentration of
50 ng/mL to maximize the response for the analyte.
Chromatographic conditions, especially the composition of
the mobile phase, column type, ﬂow rate and column oven
temperature were optimized through several trials to achieve
good resolution and increased intensity of the signals of the
analyte and IS, as well as for the short run time. Separation
was attempted using various combinations of methanol,
acetonitrile and buffer with varying contents of each compo-
nent on different columns like C8 and C18 of different makes
like Grace, Chromolith, BDS Hypersil, Hypurity advance,
Zorbax, Kromasil, Ace and Intertsil etc. It was found that a
mixture of acetonitrile and 5 mM ammonium acetate (83:17, v/v)
could achieve this purpose and was ﬁnally adopted as the mobile
phase. Zorbax SB C18 column (50 mm 2.1 mm, 5 mm) gave
good peak shape and response even at lowest concentration level
for the analyte and IS. The mobile phase was operated at a ﬂow
rate of 0.9 mL/min. The retention time of analyte and the IS were
low enough (1.13 min) allowing a small run time of 2.5 min.
Due to high drug protein binding, protein precipitation (PP)
was tried initially using acetonitrile and methanol as precipitat-
ing agents but the response was inconsistent especially at the
LLOQ level. Thus, the simple SPE technique was employed for
the sample preparation in this work and provided high
recoveries of the drugs. The use of stable labeled isotopes of
the analyte as an IS is recommended for bioanalytical assays to
increase assay precision and limit variable recovery between
analyte and the IS [25,26]. For an LC–MS/MS analysis,
utilization of stable isotope-labeled drugs as IS proves to be
helpful when a signiﬁcant matrix effect is possible. At the initial
stages of this work, several compounds were investigated to ﬁnd
a suitable IS and ﬁnally duloxetine stable labeled isotope
duloxetine d5 was found to be best for the present purpose.3.2. Selectivity and chromatography
The selectivity of the method was examined by analyzing blank
human plasma extract (Fig. 2A) and an extract spiked only with
the IS (Fig. 2B). As shown in Fig. 2A, no signiﬁcant direct
interference in the blank plasma traces was observed from
endogenous substances in drug-free human plasma at
the retention time of the analyte and IS. Similarly, Fig. 2B
shows the absence of direct interference from the IS to the
MRM channel of the analyte. Fig. 2C depicts a representative
ion-chromatogram for the LLOQ sample (0.05 ng/mL). Simi-
larly, no interference was observed from commonly used
medications such as acetaminophen, diphenhydramine,
Fig. 2 Typical MRM chromatograms of duloxetine (left panel) and IS (right panel) in human blank plasma (A), human plasma spiked
with IS (B), and an LLOQ sample along with IS (C).
R. Gajula et al.40pantoprazole, nicotine, ibuprofen, caffeine and pseudoephe-
drine (data not shown). A representative chromatogram result-
ing from the analysis of subject blank plasma sample and 5.67 h
subject plasma sample after the administration of a 60 mg oral
single dose of duloxetine is shown in Fig. 3.
3.3. Sensitivity
The lowest limit of reliable quantiﬁcation for the analyte was
set at the concentration of the LLOQ. The precision and
accuracy of analyte at LLOQ concentration was found to be
7.60% and 97.8%, respectively.
3.4. Matrix effect
Matrix effect assessment was done with the aim to check the
effect of different lots of plasma on the back calculated value of
QC’s nominal concentration. The results found were well within
the acceptable limits as shown in Table 2. No signiﬁcant matrix
effect was observed in all the six batches of human plasma forthe analyte at low and high quality control concentrations. Also,
the extraction method was rugged enough and gave accurate and
consistent results when applied to real subject samples.
3.5. Linearity
The ten-point calibration curve was found to be linear over the
concentration range of 0.05–101 ng/mL for duloxetine. After
comparing the two weighting models (1/x and 1/x2), a regression
equation with a weighting factor of 1/x2 of the drug to the IS
concentration was found to produce the best ﬁt for the
concentration–detector response relationship. The mean correla-
tion coefﬁcient of the weighted calibration curves generated during
the validation was Z0.99.
3.6. Precision and accuracy
The results for intra-day and inter-day precision and accuracy
in plasma quality control samples are summarized in Table 3.
Fig. 3 MRM chromatograms resulting from the analysis of subject blank plasma sample (A) and 5.67 h subject plasma sample (B), after
the administration of a 60 mg oral single dose of duloxetine. The sample concentration was determined to be 48.2 ng/mL.
Table 2 Matrix effect of duloxetine in human plasma (n¼3).
Plasma lot LQC (0.15 ng/mL) HQC (90.2 ng/mL)
Concentration found
(mean7SD; ng/mL)
Accuracy (%) Concentration found
(mean7SD; ng/mL)
Accuracy (%)
Lot 1 0.1770.01 109.67 96.2073.60 106.61
Lot 2 0.17070.002 113.71 96.6871.71 107.14
Lot 3 0.16070.003 107.72 98.3271.81 108.96
Lot 4 0.167 0.02 106.28 95.6970.56 106.04
Lot 5 0.1770.01 109.84 99.4572.38 110.21
Lot 6 0.1470.01 95.51 97.5172.45 108.05
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within 15% of the relative standard deviation (RSD) at low,
middle 1, middle 2 and high quality control levels, whereas
within 20% at LLOQ QCs level. The intra-day and inter-dayaccuracy deviation values were all within 100715% of the
actual values at low, middle 1, middle 2 and high quality
control levels, whereas within 100720% at LLOQ QCs level.
The results revealed good precision and accuracy.
Table 3 Precision and accuracy data for duloxetine.
Quality control Run Concentration
found (mean7SD; ng/mL)
Precision (%) Accuracy (%)
Intra-day variations (n¼6)
LLOQ
1 0.05670.002 4.20 110.48
2 0.05770.006 9.81 111.39
3 0.05170.004 7.19 100.62
4 0.04970.002 4.00 96.69
5 0.05170.002 4.39 100.75
LQC
1 0.14770.002 1.38 97.41
2 0.15370.007 4.14 101.46
3 0.15270.004 2.64 101.01
4 0.15570.004 2.32 102.80
5 0.15470.006 4.07 102.30
MQC1
1 15.1770.32 2.10 96.86
2 14.6470.61 4.18 93.45
3 15.7970.31 1.94 100.79
4 15.8670.13 0.82 101.26
5 15.9770.21 1.30 101.98
MQC2
1 48.8671.06 2.17 96.61
2 48.9371.79 3.66 96.73
3 50.3670.60 1.19 99.57
4 50.4170.76 1.51 99.67
5 46.6570.90 1.93 92.23
HQC
1 90.8773.15 3.46 100.70
2 92.1871.64 1.78 102.16
3 95.4970.93 0.97 105.82
4 94.9770.83 0.87 105.24
5 94.7171.28 1.35 104.95
Inter-day variations (n¼30)
LLOQ 0.05370.004 8.32 103.99
LQC 0.15270.005 3.53 101.00
MQC1 15.4970.61 3.95 98.87
MQC2 49.0471.73 3.53 96.96
HQC 93.6472.46 2.63 103.77
Spiked concentrations of LLOQ, LQC, MQC1, MQC2 and HQC are 0.05, 0.15, 15.66, 50.58 and 90.24 ng/mL, respectively.
Table 4 Stability data for duloxetine in plasma (n¼6).
Stability test QC (spiked
concentration, ng/mL)
Mean7SD
(ng/mL)
Accuracy/stability (%) Precision
(%)
A autosampler stability (at 10 1C for 48 h) 0.15 0.14770.006 97.37 4.21
90.24 93.2570.78 103.45 0.84
Wet extract stability (at 2–8 1C for 24 h) 0.15 0.14970.004 98.91 2.54
90.24 83.3571.50 92.36 1.80
Bench top stability (8 h at room temperature) 0.15 0.15570.004 103.11 2.30
90.24 92.6270.51 102.64 0.55
Freeze–thaw stability (three cycles) 0.15 0.14670.002 96.60 1.69
90.24 83.5471.17 92.58 1.40
Reinjection stability (24 h) 0.15 0.14070.009 93.08 6.24
90.24 87.6175.71 97.09 6.51
Long-term stability
(at 70 1C for 58 days)
0.15 0.15670.018 103.23 11.8
90.24 91.5274.80 101.42 5.24
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Six replicates at low, medium and high quality control
concentration for duloxetine were prepared for recoverydetermination. SPE with HLB cartridges was proved to be
robust and provided the cleanest samples. The mean overall
recovery of duloxetine was 86.7371.37% with the precision
range of 1.11–3.58% and the recovery of the IS was 85.01%
Quantiﬁcation of duloxetine in human plasma by LC–MS/MS 43with the precision range of 1.42–1.70%. The recoveries of
analyte and IS were good and reproducible. Therefore, the
assay has been proved to be robust in high throughput
bioanalysis.
3.8. Dilution integrity
The upper concentration limit of duloxetine can be extended to
172 ng/mL for by 1/2 and 1/4 dilutions with screened human
blank plasma. The mean back-calculated concentrations for 1/2Fig. 4 Mean plasma concentration–time proﬁle of duloxetine in
human plasma following oral administration of duloxetine hydro-
chloride (60 mg capsule) to healthy volunteers (n¼6).
Table 5 Pharmacokinetic parameters of duloxetine
(n¼6, mean7SD).
Parameter Estimated value
Cmax (ng/mL) 48.4578.27
tmax (h) 5.5070.86
AUC0t (ng h/mL) 9887205
AUC0inf (ng h/mL) 10247221
t1/2 (h) 13.8071.99
Table 6 Incurred samples reanalysis data of dul
Sample Initial conc. (ng/mL) Re-a
1 46.21 45.2
2 0.47 0.4
3 39.70 38.6
4 5.98 6.2
5 54.65 55.9
6 2.46 2.3
7 40.25 42.6
8 4.57 4.7
9 49.22 48.3
10 2.40 2.5
11 33.50 36.4
12 0.92 0.8
aExpressed as [(initial conc.re-assay conc.)/averagand 1/4 dilution samples were within 85–115% of their nominal
value. The coefﬁcients of variation (%CV) for 1/2 and 1/4
dilution samples were less than 5%.
3.9. Stability studies
In the different stability experiments carried out viz. bench top
stability (8 h), autosampler stability (48 h), freeze–thaw stabi-
lity (3 cycles), reinjection stability (24 h), wet extract stability
(24 h at 2–8 1C) and long–term stability at 70 1C for 58 days
the mean % nominal values of the analyte were found to be
within 715% of the predicted concentrations for the analyte
at their LQC and HQC levels (Table 4). Thus, the results were
found to be within the acceptable limits during the entire
validation.
Stock solutions of duloxetine and IS were found to be stable
for 15 days at 2–8 1C. The percentage stability (with the
precision range) of duloxetine and IS was 101% (1.18–1.32%)
and 97.7% (0.54–1.96%), respectively.
3.10. Pharmacokinetic study results
In order to verify the sensitivity and selectivity of this method
in a real-time situation, the present method was used to test
for duloxetine in human plasma samples collected from
healthy male volunteers (n¼6). The mean plasma concentra-
tions vs. time proﬁle of duloxetine is shown in Fig. 4 and
corresponding pharmacokinetic parameters are listed in
Table 5. These values were in close proximity when compared
with earlier reported values [7].
3.11. Incurred sample reanalysis
Since, the FDA has introduced the necessity of incurred sample
reanalysis evaluation at the Crystal City III meeting [27], it is
necessary to demonstrate assay reproducibility by using dosed
subject samples. Incurred sample reanalysis was performed
using two plasma samples from each subject and re-assayed
in a separate batch run. The differences in concentrations
between the incurred sample reanalysis and the initial values
for all the tested samples were less than 10% (Table 6),
indicating good reproducibility of the present method.oxetine.
ssay conc. (ng/mL) Differencea (%)
3 2.14
3 7.64
5 2.69
6 4.69
6 2.36
0 6.46
4 5.77
6 4.20
8 1.72
9 7.39
7 8.49
3 9.63
e] 100%.
R. Gajula et al.444. Conclusions
The LC–MS/MS assay presented in this paper is simple, rapid,
speciﬁc and sensitive for quantiﬁcation of duloxetine in human
plasma and is fully validated according to commonly accep-
table FDA guidelines. The method showed suitability for
pharmacokinetic studies in humans. The simple SPE method
gave consistent and reproducible recoveries for the analytes
from plasma. The method provided good linearity. A sample
turnover rate of less than 2.5 min makes it an attractive
procedure in high-throughput bioanalysis of duloxetine. From
the results of all the validation parameters, we can conclude
that the developed method can be useful for bioavailability
and bioequivalence (BA/BE) studies and routine therapeutic
drug monitoring with the desired precision and accuracy.
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